Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Maybury, B; Cook, G; Pratt, G; Yong, K; Ramasamy, K (2016)
Publisher: Elsevier
Languages: English
Types: Article
Consolidation with high-dose chemotherapy and autologous stem cell transplantation (ASCT) is the standard of care for transplantation-eligible patients with multiple myeloma, based on randomized trials showing improved progression-free survival with autologous transplantation after combination chemotherapy induction. These trials were performed before novel agents were introduced; subsequently, combinations of immunomodulatory drugs and proteasome inhibitors as induction therapy have significantly improved rates and depth of response. Ongoing randomized trials are testing whether conventional autologous transplantation continues to improve responses after novel agent induction. Although these results are awaited, it is important to review strategies for improving outcomes after ASCT. Conditioning before ASCT with higher doses of melphalan and combinations of melphalan with other agents, including radiopharmaceuticals, has been explored. Tandem ASCT, consolidation, and maintenance therapy after ASCT have been investigated in phase III trials. Experimental cellular therapies using ex vivo–primed dendritic cells, ex vivo–expanded autologous lymphocytes, Killer Immunoglobulin Receptor (KIR)-mismatched allogeneic natural killer cells, and genetically modified T cells to augment ASCT are also in phase I trials. This review summarizes these strategies and highlights the importance of exploring strategies to augment ASCT, even in the era of novel agent induction.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Abidi, M.H., Agarwal, R., Tageja, N., Ayash, L., Deol, A., Al-Kadhimi, Z., Abrams, J., Cronin, S., Ventimiglia, M., Lum, L., Ratanatharathorn, V., Zonder, J., Uberti, J. (2013) A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function. Biology of Blood and Marrow Transplantation, 19, 56-61.
    • Alexanian, R., Weber, D., Dimopoulos, M., Delasalle, K. & Smith, T.L. (2000) Randomized trial of alphainterferon or dexamethasone as maintenance treatment for multiple myeloma. American Journal of Hematology, 65, 204-209.
    • Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C., Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 91- 97.
    • Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.J., Grosbois, B., Bataille, R. & InterGroupe Francophone du Myelome. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. The New England Journal of Medicine, 349, 2495-2502.
    • Attal, M., Harousseau, J.L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Yakoub Agha, I., Bourhis, J.H., Garderet, L., Pegourie, B., Dumontet, C., Renaud, M., Voillat, L., Berthou, C., Marit, G., Monconduit, M., Caillot, D., Grobois, B., Avet-Loiseau, H., Moreau, P., Facon, T. & Inter-Groupe Francophone du Myelome (IFM). (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood, 108, 3289-3294.
    • Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A.M., Hulin, C., Benboubker, L., Garderet, L., Decaux, O., Leyvraz, S., Vekemans, M.C., Voillat, L., Michallet, M., Pegourie, B., Dumontet, C., Roussel, M., Leleu, X., Mathiot, C., Payen, C., Avet-Loiseau, H., Harousseau, J.L. & IFM Investigators. (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. The New England Journal of Medicine, 366, 1782-1791.
    • Attal, M., Lauwers-Cances, V., Hulin, C., Facon, T., Caillot, D., Escoffre, M., Arnulf, B., MACRO, M., Belhadj, K., Garderet, L., Roussel, M., Mathiot, C., Avet-Loiseau, H., Munshi, N.C., Richardson, P.G., Anderson, K.C., Harousseau, j.L. & Moreau, P. (2015) Autologous transplantation for multiple myeloma in the era of new drugs: A phase III study of the intergroupe francophone du myelome (IFM/DFCI 2009 trial). Blood (ASH Annual Meeting Abstracts), 126, 391.
    • Badros, A.Z., Kocoglu, M.H., Ma, N., Rapoport, A.P., Lederer, E., Philip, S., Lesho, P., Dell, C., Hardy, N.M., Yared, J., Goloubeva, O. & Singh, Z. (2015) A phase II study of anti PD-1 antibody pembrolizumab, pomalidomide and dexamethasone in patients with Relapsed/Refractory multiple myeloma (RRMM). Blood (ASH Annual Meeting Abstracts), 126, 506.
    • Baldini, L., Radaelli, F., Chiorboli, O., Fumagalli, S., Cro, L., Segala, M., Cesana, B.M., Polli, E.E. & Maiolo, A.T. (1991) No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone. Cancer, 68, 62-67.
    • Ballestrero, A., Ferrando, F., Miglino, M., Clavio, M., Gonella, R., Garuti, A., Grasso, R., Ghio, R., Balleari, E., Gobbi, M. & Patrone, F. (2002) Three-step highdose sequential chemotherapy in patients with newly diagnosed multiple myeloma. European Journal of Haematology, 68, 101-106.
    • Barlogie, B., Kyle, R.A., Anderson, K.C., Greipp, P.R., Lazarus, H.M., Hurd, D.D., McCoy, J., Dakhil, S.R., Lanier, K.S., Chapman, R.A., Cromer, J.N., Salmon, S.E., Durie, B., Crowley, J.C. (2006a) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321. Journal of Clinical Oncology, 24, 929-936.
    • Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., Van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M., Crowley, J. (2006b) Thalidomide and hematopoieticcell transplantation for multiple myeloma. New England Journal of Medicine, 354, 1021-1030.
    • Barlogie, B., Tricot, G.J., van Rhee, F., Angtuaco, E., Walker, R., Epstein, J., Shaughnessy, J.D., Jagannath, S., Bolejack, V., Gurley, J., Hoering, A., Vesole, D., Desikan, R., Siegel, D., Mehta, J., Singhal, S., Munshi, N.C., Dhodapkar, M., Jenkins, B., Attal, M., Harousseau, J.L. & Crowley, J. (2006c) Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. British Journal of Haematology, 135, 158-164.
    • Barlogie, B., Anaissie, E., van Rhee, F., Haessler, J., Hollmig, K., Pineda-Roman, M., Cottler-Fox, M., Mohiuddin, A., Alsayed, Y., Tricot, G., Bolejack, V., Zangari, M., Epstein, J., Petty, N., Steward, D., Jenkins, B., Gurley, J., Sullivan, E., Crowley, J. & Shaughnessy, J.D.,Jr. (2007) Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3. British Journal of Haematology, 138, 176- 185.
    • Barlogie, B., Anaissie, E., Haessler, J., van Rhee, F., Pineda-Roman, M., Hollmig, K., Alsayed, Y., Epstein, J., Shaughnessy, J.D.,Jr & Crowley, J. (2008) Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer, 113, 355-359.
    • Bartel, T.B., Haessler, J., Brown, T.L., Shaughnessy, J.D.,Jr, van Rhee, F., Anaissie, E., Alpe, T., Angtuaco, E., Walker, R., Epstein, J., Crowley, J. & Barlogie, B. (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood, 114, 2068-2076.
    • Beaven, A.W., Moore, D.T., Sharf, A., Serody, J.S., Shea, T.C. & Gabriel, D.A. (2011) Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma. Cancer Investigation, 29, 214-219.
    • Berdeja, J.G., Hernandez-Ilizaliturri, F., Chanan-Khan, A., Patel, M., Kelly, K.R., Running, K.L., Murphy, M., Guild, R., Carrigan, C., Ladd, S., Wolf, B.B., O'Leary, J.J. & Ailawadhi, S. (2012) Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (len) and dexamethasone (dex) in patients with CD56-positive relapsed or Relapsed/Refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 120, 728.
    • Berenson, J.R., Crowley, J.J., Grogan, T.M., Zangmeister, J., Briggs, A.D., Mills, G.M., Barlogie, B. & Salmon, S.E. (2002) Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood, 99, 3163-3168.
    • Bladé, J., Rosiñol, L., Sureda, A., Ribera, J.M., DíazMediavilla, J., García-Laraña, J., Mateos, M.V., Palomera, L., Fernández-Calvo, J., Martí, J.M., Giraldo, P., Carbonell, F., Callís, M., Trujillo, J., Gardella, S., Moro, M.J., Barez, A., Soler, A., Font, L., Fontanillas, M., San Miguel, J. (2005) High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood, 106, 3755-3759.
    • Blanes, M., Lahuerta, J.J., González, J.D., Ribas, P., Solano, C., Alegre, A., Bladé, J., San Miguel, J.F., Sanz, M.A., De La Rubia, J. (2013) Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach. Biology of Blood and Marrow Transplantation, 19, 69-74.
    • Cancer Research UK (2014) Myeloma survival statistics. WWW document. URL: http://www.cancerresearchuk.org/healthprofessional/cancer-statistics/statistics-by-cancertype/myeloma [accessed 23.4.16].
    • Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., Narni, F., Carubelli, A., Masini, L., Catalano, L., Fiacchini, M., de Vivo, A., Gozzetti, A., Lazzaro, A., Tura, S. & Baccarani, M. (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. Journal of Clinical Oncology, 25, 2434-2441.
    • Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M.T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., Offidani, M., Corradini, P., Narni, F., Spadano, A., Pescosta, N., Deliliers, G.L., Ledda, A., Cellini, C., Caravita, T., Tosi, P., Baccarani, M. (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stemcell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. The Lancet, 376, 2075-2085.
    • Chauhan, D., Ray, A., Viktorsson, K., Spira, J., PabaPrada, C., Munshi, N., Richardson, P., Lewensohn, R. & Anderson, K.C. (2013) In vitro and in vivo antitumor activity of a novel alkylating agent, melphalanflufenamide, against multiple myeloma cells. Clinical Cancer Research, 19, 3019-3031.
    • Chen, A.I., Negrin, R.S., McMillan, A., Shizuru, J.A., Johnston, L.J., Lowsky, R., Miklos, D.B., Arai, S., Weng, W.K., Laport, G.G. & Stockerl-Goldstein, K. (2012) Tandem chemo-mobilization followed by highdose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplantation, 47, 516-521.
    • Chérel, M., Gouard, S., Gaschet, J., Sai-Maurel, C., Bruchertseifer, F., Morgenstern, A., Bourgeois, M., Gestin, J.F., Bodere, F.K., Barbet, J., Moreau, P. & Davodeau, F. (2013) 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. Journal of Nuclear Medicine, 54, 1597-1604.
    • Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T., Selby, P.J. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine, 348, 1875-1883.
    • Comenzo, R.L., Hassoun, H., Kewalramani, T., Klimek, V., Dhodapkar, M., Reich, L., Teruya-Feldstein, J., Fleisher, M., Filippa, D., Nimer, S.D. (2006) Results of a phase I/II trial adding carmustine (300mg/m2) to melphalan (200mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. Leukemia, 20, 345-349.
    • Desikan, K.R., Tricot, G., Dhodapkar, M., Fassas, A., Siegel, D., Vesole, D.H., Jagannath, S., Singhal, S., Mehta, J., Spoon, D., Anaissie, E., Barlogie, B., Munshi, N. (2000) Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MELCY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplantation, 25, 483-487.
    • Dimopoulos, M., Siegel, D.S., Lonial, S., Qi, J., Hajek, R., Facon, T., Rosinol, L., Williams, C., Blacklock, H., Goldschmidt, H., Hungria, V., Spencer, A., Palumbo, A., Graef, T., Eid, J.E., Houp, J., Sun, L., Vuocolo, S. & Anderson, K.C. (2013) Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double-blind study. The Lancet.Oncology, 14, 1129-1140.
    • Dispenzieri, A., Wiseman, G.A., Lacy, M.Q., Hayman, S.R., Kumar, S.K., Buadi, F., Dingli, D., Laumann, K.M., Allred, J., Geyer, S.M., Litzow, M.R., Gastineau, D.A., Inwards, D.J., Micallef, I.N., Ansell, S.M., Porrata, L., Elliott, M.A., Johnston, P.B., Hogan, W.J. & Gertz, M.A. (2010) A phase II study of 153SmEDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. American Journal of Hematology, 85, 409- 413.
    • Dispenzieri, A., Gertz, M.A., Lacy, M.Q., Laumann, K., LaPlant, B.R., Kumar, S., Buadi, F.K., Hayman, S.R., Dingli, D., Hogan, W.J., Ansell, S.M., Gastineau, D.A., Inwards, D.J., Micallef, I.N., Porrata, L.F., Johnston, P.B., Litzow, M.R. & Witzig, T.E. (2011) A phase I trial of zevalin radioimmunotherapy with high-dose melphalan (HDM) and autologous stem cell transplant (ASCT) for multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 118, 3095.
    • Donato, M.L., Aleman, A., Champlin, R.E., Weber, D., Alexanian, R., Ippoliti, C.M., de Lima, M., Anagnostopoulos, A., Giralt, S. (2004) High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: A new regimen for the treatment of multiple myeloma. Leukemia and Lymphoma, 45, 755-759.
    • Drayson, M.T., Chapman, C.E., Dunn, J.A., Olujohungbe, A.B. & Maclennan, I.C. (1998) MRC trial of alpha2binterferon maintenance therapy in first plateau phase of multiple myeloma. MRC working party on leukaemia in adults. British Journal of Haematology, 101, 195- 202.
    • Durie, B.G., Jacobson, J., Barlogie, B. & Crowley, J. (2004) Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in southwest oncology group chemotherapy trials. Journal of Clinical Oncology, 22, 1857-1863.
    • Fenk, R., Schneider, P., Kropff, M., Huenerlituerkoglu, A.N., Steidl, U., Aul, C., Hildebrandt, B., Haas, R., Heyll, A., Kobbe, G. (2005) High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: Results of a randomised study. British Journal of Haematology, 130, 588-594.
    • Fermand, J.-P., Katsahian, S., Divine, M., Leblond, V., Dreyfus, F., Macro, M., Arnulf, B., Royer, B., Mariette, X., Pertuiset, E., Belanger, C., Janvier, M., Chevret, S., Brouet, J.C., Ravaud, P. (2005a) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the group myelome-autogreffe. Journal of Clinical Oncology, 23, 9227-9233.
    • Fermand, J.-P. on behalf of the Myélome Autogreffe Group (2005b) High does therapy supported with autologous blood stem cell transplantation in multiple myeloma: long term follow-up of the prospective studies of the MAG group [Xth International Myeloma Foundation Workshop, Sydney 2005]. WWW document. http://myeloma.org/pdfs/ Sydney2005˙Fermand˙P8.pdf [accessed 20.6.2015].
    • Forsberg, P., Guarneri, D., Rossi, A., Pearse, R., Perry, A., Pekle, K., Greenberg, J., Shore, T., Gergis, U., Mayer, S., Van Besien, K., Jayabalan, D., Coleman, M., Ely, S., Niesvizky, R. & Mark, T.M. (2015) A phase I study of the addition of high-dose lenalidomide to melphalan conditioning for autologous stem-cell transplant in relapsed or refractory multiple myeloma. Clinical Lymphoma Myeloma and Leukemia, 15, e291-e292.
    • Garfall, A.L., Maus, M.V., Hwang, W.T., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., Zheng, Z., Vogl, D.T., Cohen, A.D., Weiss, B.M., Dengel, K., Kerr, N.D., Bagg, A., Levine, B.L., June, C.H. & Stadtmauer, E.A. (2015) Chimeric antigen receptor T cells against CD19 for multiple myeloma. The New England Journal of Medicine, 373, 1040-1047.
    • Garg, T.K., Szmania, S.M., Khan, J.A., Hoering, A., Malbrough, P.A., Moreno-Bost, A., Greenway, A.D., Lingo, J.D., Li, X., Yaccoby, S., Suva, L.J., Storrie, B., Tricot, G., Campana, D., Shaughnessy, J.D.,Jr, Nair, B.P., Bellamy, W.T., Epstein, J., Barlogie, B. & van Rhee, F. (2012) Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica, 97, 1348-1356.
    • Gay, F., Magarotto, V., Petrucci, M.T., Di Raimondo,F., Pour, L., Caravita, T., Scudla, V., Cafro, A.M., Liberati, A.M., Spada, S., Vladimir, M., Pescosta, N., Ria, R., Offidani, M., Bringhen, S., Bernardini, A., Patriarca, F., Corradini, P., Foà, R., Cascavilla, N., Catalano, L., Spencer, A., Hajek, R., Boccadoro, M. & Palumbo, A. (2015) Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial. Blood (ASH Annual Meeting Abstracts), 126, 392.
    • Giralt, S., Bensinger, W., Goodman, M., Podoloff, D., Eary, J., Wendt, R., Alexanian, R., Weber, D., Maloney, D., Holmberg, L., Rajandran, J., Breitz, H., Ghalie, R. & Champlin, R. (2003) 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: Results of two phase 1/2 trials. Blood, 102, 2684-2691.
    • Goel, A., Dispenzieri, A., Geyer, S.M., Greiner, S., Peng, K.W. & Russell, S.J. (2006) Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Blood, 107, 4063-4070.
    • Govindarajan, R., Jagannath, S., Flick, J.T., Vesole, D.H., Sawyer, J., Barlogie, B. & Tricot, G. (1996) Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. British Journal of Haematology, 95, 349-353.
    • Green, D.J., Jones, J.C., Hylarides, M.D., Hamlin, D.K., Wilbur, D.S., Lin, Y., Kenoyer, A.L., Frayo, S.L., Bensinger, W.I., Gopal, A.K., Orozco, J.J., Gooley, T.A., Wood, B.L., Pagel, J.M. & Press, O.W. (2013) Anti-CD38 pretargeted radioimmunotherapy eradicates multiple myeloma xenografts in a murine model. Blood (ASH Annual Meeting Abstracts), 122, 882.
    • Harousseau, J.L., Avet-Loiseau, H., Attal, M., Charbonnel, C., Garban, F., Hulin, C., Michallet, M., Facon, T., Garderet, L., Marit, G., Ketterer, N., Lamy, T., Voillat, L., Guilhot, F., Doyen, C., Mathiot, C. & Moreau, P. (2009) Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with highdose therapy: Long-term analysis of the IFM 99-02 and 99-04 trials. Journal of Clinical Oncology, 27, 5720- 5726.
    • Harousseau, J.-L., Attal, M., Avet-Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T., Casassus, P., Michallet, M., Maisonneuve, H., Benboubker, L., Maloisel, F., Petillon, M.-O., Webb, I., Mathiot, C., Moreau, P. (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005- 01 phase III trial. Journal of Clinical Oncology, 28, 4621-4629.
    • Huang, W., Li, J., Li, H., Kang, W., Bo, J., Zhao, Y., Gao, C., Zhou, D. & Yu, L. (2012) High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy. Leukemia & Lymphoma, 53, 2507- 2510.
    • Jakubowiak, A.J., Benson, D.M., Bensinger, W., Siegel, D.S., Zimmerman, T.M., Mohrbacher, A., Richardson, P.G., Afar, D.E., Singhal, A.K. & Anderson, K.C. (2012) Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. Journal of Clinical Oncology, 30, 1960-1965.
    • Kazmi, S.M., Saliba, R.M., Donato, M., Wang, M., Hosing, C., Qureshi, S., Anderlini, P., Popat, U., Champlin, R.E., Giralt, S.A. & Qazilbash, M.H. (2011) Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplantation, 46, 510-515.
    • Kelly, K.R., Chanan-Khan, A., Heffner, L.T., Somlo, G., Siegel, D.S., Zimmerman, T., Karnad, A., Munshi, N.C., Jagannath, S., Greenberg, A.L., Lonial, S., Roy, V., Ailawadhi, S., Barmaki-Rad, F., Chavan, S., Patel, P., Wartenberg-Demand, A., Haeder, T. & Anderson, K.C. (2014) Indatuximab ravtansine (BT062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma: Clinical activity in patients already exposed to lenalidomide and bortezomib. Blood (ASH Annual Meeting Abstracts), 124, 4736.
    • Knop, S., Bauer, K., Hebart, H., Wandt, H., Trumper, L., Liebisch, P., Maschmeyer, G., Peest, D., Wolf, H.H., Kroger, N., Straka, C., Pfreundschuh, M., Coser, P., Meisner, C., Kanz, L. & Einsele, H. (2007) A randomized comparison of total-marrow irradiation, busulfan and cyclophosphamide with tandem high-dose melphalan in patients with multiple myeloma. Blood (ASH Annual Meeting Abstracts), 110, 728.
    • Kochenderfer, J.M., Dudley, M.E., Kassim, S.H., Carpenter, R.O., Yang, J.C., Phan, G.Q., Hughes, M.S., Sherry, R.M., Feldman, S., Spaner, D., Nathan, D.N., Morton, K.E., Toomey, M.A. & Rosenberg, S.A. (2013) Effective treatment of chemotherapy-refractory diffuse large B-cell lymphoma with autologous T cells genetically-engineered to express an anti-CD19 chimeric antigen receptor. Blood (ASH Annual Meeting Abstracts), 122, 168-168.
    • Kumar, A., Kharfan-Dabaja, M.A., Glasmacher, A. & Djulbegovic, B. (2009) Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. Journal of the National Cancer Institute, 101, 100-106.
    • Lacy, M.Q., Mandrekar, S., Dispenzieri, A., Hayman, S., Kumar, S., Buadi, F., Dingli, D., Litzow, M., Wettstein, P., Padley, D., Kabat, B., Gastineau, D., Rajkumar, S.V. & Gertz, M.A. (2009) Idiotype-pulsed antigenpresenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. American Journal of Hematology, 84, 799-802.
    • Ladetto, M., Pagliano, G., Ferrero, S., Cavallo, F., Drandi, D., Santo, L., Crippa, C., De Rosa, L., Pregno, P., Grasso, M., Liberati, A.M., Caravita, T., Pisani, F., Guglielmelli, T., Callea, V., Musto, P., Cangialosi, C., Passera, R., Boccadoro, M. & Palumbo, A. (2010) Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. Journal of Clinical Oncology, 28, 2077-2084.
    • Lahuerta, J.J., Mateos, M.V., Martinez-Lopez, J., Rosinol, L., Sureda, A., de la Rubia, J., Garcia-Larana, J., Martinez-Martinez, R., Hernandez-Garcia, M.T., Carrera, D., Besalduch, J., de Arriba, F., Ribera, J.M., Escoda, L., Hernandez-Ruiz, B., Garcia-Frade, J., Rivas-Gonzalez, C., Alegre, A., Bladé, J. & San Miguel, J.F. (2008) Influence of pre- and posttransplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival. Journal of Clinical Oncology, 26, 5775-5782.
    • Lahuerta, J.J., Mateos, M.V., Martínez-López, J., Grande, C., de la Rubia, J., Rosiñol, L., Sureda, A., GarcíaLaraña, J., Díaz-Mediavilla, J., Hernández-García, M.T., Carrera, D., Besalduch, J., de Arriba, F., Oriol, A., Escoda, L., García-Frade, J., Concepción RivasGonzález Adrían, A., Bladé, J., San Miguel, J.F. (2010) Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica, 95, 1913-1920.
    • Lebovic, D., Kaminski, M.S., Anderson, T.B., DetweilerShort, K., Griffith, K.A., Jobkar, T.L., Kandarpa, M. & Jakubowiak, A. (2012) A phase II study of consolidation treatment with iodione-131 tositumomab (bexxar™) in multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 120, 1854.
    • Leleu, X., Fouquet, G., Hebraud, B., Roussel, M., Caillot, D., Chretien, M.L., Arnulf, B., Szalat, R., Garderet, L., Benajiba, L., Pegourie, B., Regny, C., Royer, B., Caulier, A., Stoppa, A.M., Garciaz, S., Touzeau, C., Chaleteix, C., Fermand, J.P., Loiseau, H.A., Facon, T., Attal, M., Moreau, P. & Intergroupe Francophone du Myelome (IFM). (2013) Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. Leukemia, 27, 2242-2244.
    • Lokhorst, H.M., Schmidt-Wolf, I., Van Der Holt, P.S., Martin, H., Barge, R., Bertsch, U., Schlenzka, J., Bos, G.M.J., Croockewit, S., Zweegman, S., Breitkreuz, I., Joosten, P., Scheid, C., Van Marwijk-Kooy, M., Salwender, H.-J., Van Oers, M.H.J., Schaafsma, R., Naumann, R., Sinnige, H., Blau, I., Verhoef, G., De Weerdt, O., Wijermans, P., Wittebol, S., Duersen, U., Vellenga, E., Goldschmidt, H. (2008) Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
    • Haematologica, 93, 124-127.
    • Lokhorst, H.M., Plesner, T., Laubach, J.P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M.C., Lassen, U., Krejcik, J., Palumbo, A., van de Donk, N.W., Ahmadi, T., Khan, I., Uhlar, C.M., Wang, J., Sasser, A.K., Losic, N., Lisby, S., Basse, L., Brun, N. & Richardson, P.G. (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. The New England Journal of Medicine, 373, 1207-1219.
    • Lonial, S., Kaufman, J., Tighiouart, M., Nooka, A., Langston, A.A., Heffner, L.T., Torre, C., McMillan, S., Renfroe, H., Harvey, R.D., Lechowicz, M.J., Khoury, H.J., Flowers, C.R. & Waller, E.K. (2010) A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: A dose- and schedule-finding study. Clinical Cancer Research, 16, 5079-5086.
    • Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.V., Magen, H., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R.Z., Taniwaki, M., Rollig, C., Einsele, H., Wu, K.L., Singhal, A., San-Miguel, J., Matsumoto, M., Katz, J., Bleickardt, E., Poulart, V., Anderson, K.C., Richardson, P. & ELOQUENT-2 Investigators. (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. The New England Journal of Medicine, 373, 621-631.
    • Ma, M.H., Yang, H.H., Parker, K., Manyak, S., Friedman, J.M., Altamirano, C., Wu, Z.Q., Borad, M.J., Frantzen, M., Roussos, E., Neeser, J., Mikail, A., Adams, J., Sjak-Shie, N., Vescio, R.A. & Berenson, J.R. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clinical Cancer Research, 9, 1136-1144.
    • Magarotto, V., Sonneveld, P., Paba-Prada, C., Plesner, T., Mellqvist, U-H., Byrne, C., Harmenberg, J., Nordström, E., Palumbo, A. & Richardson, P.G. (2015) Encouraging preliminary data in ongoing open-label phase 1/2 study of safety and efficacy of melflufen and dexamethasone for patients with relapsed and relapsed-refractory multiple myeloma. Haematologica (EHA Abstracts), 100(s1):89
    • Mai, E.K., Benner, A., Bertsch, U., Brossart, P., Hänel, A., Kunzmann, V., Naumann, R., Neben, K., Egerer, G., Ho, A.D., Hillengass, J., Raab, M.S., Neubauer, A., Peyn, A., Ko, Y., Peter, N., Scheid, C. & Goldschmidt, H. (2016) Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: Long-term results from the phase III GMMG-HD2 trial. British Journal of Haematology, published on-line ahead of print.
    • Maiolino, A., Hungria, V.T., Garnica, M., OliveiraDuarte, G., Oliveira, L.C., Mercante, D.R., Miranda, E.C., Quero, A.A., Peres, A.L., Barros, J.C., Tanaka, P., Magalhaes, R.P., Rego, E.M., Lorand-Metze, I., Lima, C.S., Renault, I.Z., Braggio, E., Chiattone, C., Nucci, M., de Souza, C.A. & Brazilian Multiple Myeloma Study Group (BMMSG/GEMOH). (2012) Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. American Journal of Hematology, 87, 948-952.
    • Marin, G.H., Menna, M.E., Bergna, M.I., Malacalza, J., Martin, C., Mendez, M.C., Klein, G., Montero-Labat, L., Gil, M.A., Saba, S., Gardenal, L., Mansilla, E., Orlando, S., Canepa, C. & Piccinelli, G. (2001) Induction of anti-tumor activity following autologous stem cell transplantation: Immunotherapeutic implications. Transplantation Proceedings, 33, 2004- 2007.
    • Mark, T.M., Reid, W., Niesvizky, R., Gergis, U., Pearse, R., Mayer, S., Greenberg, J., Coleman, M., Van Besien, K. & Shore, T. (2013) A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biology of Blood and Marrow Transplantation, 19, 831-837.
    • June, C.H., Porter, D.L. & Grupp, S.A. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England Journal of Medicine, 371, 1507-1517.
    • McCann, K.J., Godeseth, R., Chudley, L., Mander, A., Di Genova, G., Lloyd-Evans, P., Kerr, J.P., Malykh, V.B., Jenner, M.W., Orchard, K.H., Stevenson, F.K. & Ottensmeier, C.H. (2015) Idiotypic DNA vaccination for the treatment of multiple myeloma: Safety and immunogenicity in a phase I clinical study. Cancer Immunology, Immunotherapy, 64, 1021-1032.
    • McCarthy, P.L., Owzar, K., Hofmeister, C.C., Hurd, D.D., Hassoun, H., Richardson, P.G., Giralt, S., Stadtmauer, E.A., Weisdorf, D.J., Vij, R., Moreb, J.S., Callander, N.S., Van Besien, K., Gentile, T., Isola, L., Maziarz, R.T., Gabriel, D.A., Bashey, A., Landau, H., Martin, T., Qazilbash, M.H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M.C., Horowitz, M.M., Shea, T.C., Devine, S.M., Anderson, K.C. & Linker, C. (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. The New England Journal of Medicine, 366, 1770-1781.
    • Mellqvist, U.H., Gimsing, P., Hjertner, O., Lenhoff, S., Laane, E., Remes, K., Steingrimsdottir, H., Abildgaard, N., Ahlberg, L., Blimark, C., Dahl, I.M., Forsberg, K., Gedde-Dahl, T., Gregersen, H., Gruber, A., Guldbrandsen, N., Haukas, E., Carlson, K., Kvam, A.K., Nahi, H., Lindas, R., Andersen, N.F., Turesson, I., Waage, A., Westin, J. & Nordic Myeloma Study Group. (2013) Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: A nordic myeloma study group randomized phase 3 trial. Blood, 121, 4647-4654.
    • Mihara, K., Bhattacharyya, J., Kitanaka, A., Ihara, A., Sakai, A., Kuroda, Y., Asaoku, H., Takihara, Y. & Kimura, A. (2011) T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Blood (ASH Annual Meeting Abstracts), 118, 885.
    • Mitsiades, N., Mitsiades, C.S., Richardson, P.G., Poulaki, V., Tai, Y.T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Schlossman, R., Munshi, N.C., Hideshima, T. & Anderson, K.C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood, 101, 2377-2380.
    • Miyamoto, T., Yoshimoto, G., Kamimura, T., Muta, T., Takashima, S., Ito, Y., Shiratsuchi, M., Choi, I., Kato, K., Takenaka, K., Iwasaki, H., Takamatsu, Y., Teshima, T. & Akashi, K. (2013) Combination of highdose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. International Journal of Hematology, 98, 337-345.
    • Moreau, P., Facon, T., Attal, M., Hulin, C., Michallet, M., Maloisel, F., Sotto, J.-J., Guilhot, F., Marit, G., Doyen, C., Jaubert, J., Fuzibet, J.-G., François, S., Benboubker, L., Monconduit, M., Voillat, L., Macro, M., Berthou, C., Dorvaux, V., Pignon, B., Rio, B., Matthes, T., Casassus, P., Caillot, D., Najman, N., Grosbois, B., Bataille, R., Harousseau, J.-L. (2002) Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood, 99, 731-735.
    • Moreau, P., Mateos, M., Bladé, J., Benboubker, L., de la Rubia, J., Facon, T., Comenzo, R.L., Fay, J.W., Qin, X., Masterson, T., Schecter, J., Ahmadi, T. & San Miguel, J. (2014) An open-label, multicenter, phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma. Blood (ASH Annual Meeting Abstracts), 124, 176.
    • Morgan, G.J., Davies, F.E., Gregory, W.M., Bell, S.E., Szubert, A.J., Coy, N.N., Cook, G., Feyler, S., Johnson, P.R.E., Rudin, C., Drayson, M.T., Owen, R.G., Ross, F.M., Russell, N.H., Jackson, G.H., Anthony Child, J. (2012) Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica, 97, 442- 450.
    • Nair, B., van Rhee, F., Shaughnessy, J.D.,Jr, Anaissie, E., Szymonifka, J., Hoering, A., Alsayed, Y., Waheed, S., Crowley, J. & Barlogie, B. (2010) Superior results of total therapy 3 (2003-33) in gene expression profilingdefined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood, 115, 4168-4173.
    • Nath, C.E., Shaw, P.J., Trotman, J., Zeng, L., Duffull, S.B., Hegarty, G., McLachlan, A.J., Gurney, H., Kerridge, I., Kwan, Y.L., Presgrave, P., Tiley, C., Joshua, D., Earl, J. (2010) Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 69, 484-497.
    • Nishihori, T., Alekshun, T.J., Shain, K., Sullivan, D.M., Baz, R., Perez, L., Pidala, J., Kharfan-Dabaja, M.A., Ochoa-Bayona, J.L., Fernandez, H.F., Yarde, D.N., Oliveira, V., Fulp, W., Han, G., Kim, J., Chen, D.T., Raychaudhuri, J., Dalton, W., Anasetti, C. & Alsina, M. (2012) Bortezomib salvage followed by a phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. British Journal of Haematology, 157, 553-563.
    • Nooka, A.K., Kaufman, J.L., Muppidi, S., Langston, A., Heffner, L.T., Gleason, C., Casbourne, D., Saxe, D., Boise, L.H. & Lonial, S. (2014) Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia, 28, 690-693.
    • Orchard, K., Cooper, M., Lewington, V., Tristram, M., Zivanovic, M., Thom, J., Quadri, S., Richardson, D., Causer, L. & Johnson, P. (2005) Targeted radiotherapy in the conditioning prior to haematopoietic stem cell transplantation: Results of a phase I radiation dose escalation study using yttrium-90-labelled anti-CD66 monoclonal antibody demonstrating high BM uptake of radiation. Blood (ASH Annual Meeting Abstracts), 106, 2189.
    • Paiva, B., Gutierrez, N.C., Rosinol, L., Vidriales, M.B., Montalban, M.A., Martinez-Lopez, J., Mateos, M.V., Cibeira, M.T., Cordon, L., Oriol, A., Terol, M.J., Echeveste, M.A., de Paz, R., de Arriba, F., Palomera, L., de la Rubia, J., Diaz-Mediavilla, J., Sureda, A., Gorosquieta, A., Alegre, A., Martin, A., Hernandez, M.T., Lahuerta, J.J., Bladé, J., San Miguel, J.F. & PETHEMA/GEM (Programa para el Estudio de la Terapeutica en Hemopatias Malignas/Grupo Espanol de Mieloma) Cooperative Study Groups. (2012) High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood, 119, 687- 691.
    • Palumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Yehuda, D.B., Petrucci, M.T., Pezzatti, S., Caravita, T., Cerrato, C., Ribakovsky, E., Genuardi, M., Cafro, A., Marcatti, M., Catalano, L., Offidani, M., Carella, A.M., Zamagni, E., Patriarca, F., Musto, P., Evangelista, A., Ciccone, G., Omedé, P., Crippa, C., Corradini, P., Nagler, A., Boccadoro, M., Cavo, M. (2014a) Autologous transplantation and maintenance therapy in multiple myeloma. New England Journal of Medicine, 371, 895-905.
    • Palumbo, A., Gay, F., Musto, P., Caravita, T., Larocca, A., Rossi, D., Ben Yehuda, D., Offidani, M., Donato, F., Finsinger, P., Omede, P., Conticello, C., Nagler, A., Ria, R., Cavalli, M., Mina, R., Petrucci, M.T., Hardan, I., Cavallo, F. & Boccadoro, M. (2014b) Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints. Journal of Clinical Oncology (ASCO Meeting Abstracts), 32, 8515.
    • Pica, G., Vagge, S., Beltrami, G., Nati, S., Catania, G., Corvò, R. & Carella, A.M. (2011) A phase I study of hypofractionated tailored total marrow or total lymphoid irradiation with helical tomotherapy plus chemotherapy as a conditioning regimen for autologous stem cell transplantation. Blood (ASH Annual Meeting Abstracts), 118, 4523.
    • Pineda-Roman, M., Barlogie, B., Anaissie, E., Zangari, M., Bolejack, V., van Rhee, F., Tricot, G. & Crowley, J. (2008) High-dose melphalan-based autotransplants for multiple myeloma: The Arkansas experience since 1989 in 3077 patients. Cancer, 112, 1754-1764.
    • Plesner, T., Arkenau, H., Lokhorst, H.M., Gimsing, P., Krejcik, J., Lemech, C., Minnema, M.C., Lassen, U., Laubach, J.P., Ahmadi, T., Yeh, H., Guckert, M.E., Feng, H., Brun, N.C., Lisby, S., Basse, L., Palumbo, A. & Richardson, P.G. (2014) Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts), 124, 84.
    • Popat, R., Cavenagh, J.D., Owen, R.G., Streetly, M., Schey, S.A., Koh, M., Crowe, J., Quinn, M.F., D'Sa, S., Virchis, A., Cook, G., Crawley, C., Pratt, G., Cook, M., Oakervee, H.E., Counsell, N., Adedayo, T., Evans, A., Braganca, N., Smith, P., lyons-Lewis, J., Rabin, N. & Yong, K.L. (2014) Subcutaneous PAD as induction therapy for patients with newly diagnosed myeloma: A phase 2 trial assessing the impact of minimal residual disease (MRD) in patients with deferred autologous stem cell transplantation (PADIMAC). Blood (ASH Annual Meeting Abstracts), 124, 4745.
    • Pulte, D., Jansen, L., Castro, F.A., Emrich, K., Katalinic, A., Holleczek, B., Brenner, H., Geiss, K., Meyer, M., Eberle, A., Luttmann, S., Stabenow, R., Hentschel, S., Nennecke, A., Kieschke, J., Sirri, E., Kajüter, H., Mattauch, V., Eisemann, N., Kraywinkel, K., Gondos, A., Krilaviciute, A. (2015) Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century. British Journal of Haematology, 171, 189-196.
    • Qazilbash, M.H., Saliba, R.M., Nieto, Y., Parikh, G., Pelosini, M., Khan, F.B., Jones, R.B., Hosing, C., Mendoza, F., Weber, D.M., Wang, M., Popat, U., Alousi, A., Anderlini, P., Champlin, R.E. & Giralt, S. (2008) Arsenic trioxide with ascorbic acid and highdose melphalan: Results of a phase II randomized trial. Biology of Blood and Marrow Transplantation, 14, 1401-1407.
    • Rabin, N., Percy, L., Khan, I., Quinn, J., D'Sa, S. & Yong, K.L. (2012) Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma. British Journal of Haematology, 158, 499-505.
    • Rapoport, A.P., Aqui, N.A., Stadtmauer, E.A., Vogl, D.T., Fang, H.B., Cai, L., Janofsky, S., Chew, A., Storek, J., Akpek, G., Badros, A., Yanovich, S., Tan, M.T., Veloso, E., Pasetti, M.F., Cross, A., Philip, S., Murphy, H., Bhagat, R., Zheng, Z., Milliron, T., Cotte, J., Cannon, A., Levine, B.L., Vonderheide, R.H. & June, C.H. (2011) Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood, 117, 788-797.
    • Rapoport, A.P., Aqui, N.A., Stadtmauer, E.A., Vogl, D.T., Xu, Y.Y., Kalos, M., Cai, L., Fang, H.B., Weiss, B.M., Badros, A., Yanovich, S., Akpek, G., Tsao, P., Cross, A., Mann, D., Philip, S., Kerr, N., Brennan, A., Zheng, Z., Ruehle, K., Milliron, T., Strome, S.E., Salazar, A.M., Levine, B.L. & June, C.H. (2014) Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clinical Cancer Research, 20, 1355-1365.
    • Rawstron, A.C., Gregory, W.M., de Tute, R.M., Davies, F.E., Bell, S.E., Drayson, M.T., Cook, G., Jackson, G.H., Morgan, G.J., Child, J.A. & Owen, R.G. (2015) Minimal residual disease in myeloma by flow cytometry: Independent prediction of survival benefit per log reduction. Blood, 125, 1932-1935.
    • Riccardi, A., Mora, O., Tinelli, C., Porta, C., Danova, M., Brugnatelli, S., Grasso, D., Tolca, B., Spanedda, R., De Paoli, A., Barbarano, L., Cavanna, L., Giordano, M., Delfini, C., Nicoletti, G., Bergonzi, C., Rinaldi, E., Piccinini, L. & Ascari, E. (2003) Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: Results of the MM87 prospective randomised protocol. European Journal of Cancer, 39, 31-37.
    • Roussel, M., Moreau, P., Huynh, A., Mary, J.Y., Danho, C., Caillot, D., Hulin, C., Fruchart, C., Marit, G., Pegourie, B., Lenain, P., Araujo, C., Kolb, B., Randriamalala, E., Royer, B., Stoppa, A.M., Dib, M., Dorvaux, V., Garderet, L., Mathiot, C., Avet-Loiseau, H., Harousseau, J.L., Attal, M. & Intergroupe Francophone du Myelome (IFM). (2010) Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood, 115, 32-37.
    • Rueff, J., Medinger, M., Heim, D., Passweg, J. & Stern, M. (2014) Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Biology of Blood and Marrow Transplantation, 20, 896-899.
    • San-Miguel, J.F., Hungria, V.T., Yoon, S.S., Beksac, M., Dimopoulos, M.A., Elghandour, A., Jedrzejczak, W.W., Gunther, A., Nakorn, T.N., Siritanaratkul, N., Corradini, P., Chuncharunee, S., Lee, J.J., Schlossman, R.L., Shelekhova, T., Yong, K., Tan, D., Numbenjapon, T., Cavenagh, J.D., Hou, J., LeBlanc, R., Nahi, H., Qiu, L., Salwender, H., Pulini, S., Moreau, P., Warzocha, K., White, D., Bladé, J., Chen, W., de la Rubia, J., Gimsing, P., Lonial, S., Kaufman, J.L., Ocio, E.M., Veskovski, L., Sohn, S.K., Wang, M.C., Lee, J.H., Einsele, H., Sopala, M., Corrado, C., Bengoudifa, B.R., Binlich, F. & Richardson, P.G. (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial. The Lancet.Oncology, 15, 1195-1206.
    • San Miguel, J., Mateos, M., Shah, J.J., Ocio, E.M., Rodriguez-Otero, P., Reece, D., Munshi, N.C., Avigan, D., Ge, Y., Balakumaran, A., Marinello, P., Orlowski, R.Z. & Siegel, D. (2015) Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for Relapsed/Refractory multiple myeloma (RRMM). Blood (ASH Annual Meeting Abstracts), 126, 505.
    • Sborov, D.W., Benson, D.M., Williams, N., Huang, Y., Bowers, M.A., Humphries, K., Efebera, Y., Devine, S. & Hofmeister, C.C. (2015) Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. British Journal of Haematology, 171, 74-83.
    • Scheid, C., Sonneveld, P., Schmidt-Wolf, I.G., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Blau, I.W., Vellenga, E., Weisel, K., Pfreundschuh, M., Jie, K.S., Neben, K., van de Velde, H., Duehrsen, U., Schaafsma, M.R., Lindemann, W., Kersten, M.J., Peter, N., Hanel, M., Croockewit, S., Martin, H., Wittebol, S., Bos, G.M., van MarwijkKooy, M., Wijermans, P., Goldschmidt, H. & Lokhorst, H.M. (2014) Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: A subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica, 99, 148-154.
    • Shi, J., Tricot, G., Szmania, S., Rosen, N., Garg, T.K., Malaviarachchi, P.A., Moreno, A., Dupont, B., Hsu, K.C., Baxter-Lowe, L.A., Cottler-Fox, M., Shaughnessy, J.D. Jr, Barlogie, B. & van Rhee, F. (2008) Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. British Journal of Haematology, 143, 641-653.
    • Sonneveld, P., Van Der Holt, B., Segeren, C.M., Vellenga, E., Croockewit, A.J., Verhoef, G.E.G., Cornelissen, J.J., Schaafsma, M.R., Van Oers, M.H.J., Wijermans, P.W., Westveer, P.H.M., Lokhorst, H.M. (2007) Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: Longterm follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica, 92, 928-935.
    • Sonneveld, P., Schmidt-Wolf, I.G.H., Van Der Holt, B., El Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I.W., Weisel, K.C., Wittebol, S., Bos, G.M.J., Stevens-Kroef, M., Scheid, C., Pfreundschuh, M., Hose, D., Jauch, A., Van Der Velde, H., Raymakers, R., Schaafsma, M.R., Kersten, M.-J., Van Marwijk-Kooy, M., Duehrsen, U., Lindemann, W., Wijermans, P.W., Lokhorst, H.M., Goldschmidt, H.M. (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/ GMMG-HD4 trial.Journal of Clinical Oncology, 30, 2946-2955.
    • Sonneveld, P., Scheid, C., van der Holt, B., Jarari, L.e., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Wolfgang Blau, I., Weisel, K., Wittebol, S., Bos, G.M.J., Stevens, M., Schmidt-Wolf, I.G., Pfreundschuh, M., Hose, D., Jauch, A., van de Velde, H., Raymakers, R., Schaafsma, M.R., Kersten, M.J., van Marwijk Kooy, M., Duehrsen, U., Lindemann, H.W., Wijermans, P.W., Lokhorst, H. & Goldschmidt, H. (2013) Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma:Extended follow-up of the HOVON-65/GMMG-HD4 trial. Blood (ASH Annual Meeting Abstracts), 122, 404.
    • Spencer, A., Horvath, N., Gibson, J., Prince, H.M., Herrmann, R., Bashford, J., Joske, D., Grigg, A., McKendrick, J., Prosser, I., Lowenthal, R., Deveridge, S., Taylor, K. (2005) Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplantation, 35, 971-977.
    • Spencer, A., Prince, H.M., Roberts, A.W., Prosser, I.W., Bradstock, K.F., Coyle, L., Gill, D.S., Horvath, N., Reynolds, J. & Kennedy, N. (2009) Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. Journal of Clinical Oncology, 27, 1788-1793.
    • Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Masszi, T., Spicka, I., Oriol, A., Hajek, R., Rosinol, L., Siegel, D.S., Mihaylov, G.G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A.J., San-Miguel, J.F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., Bensinger, W.I., Mateos, M.V., BenYehuda, D., Kukreti, V., Zojwalla, N., Tonda, M.E., Yang, X., Xing, B., Moreau, P., Palumbo, A. & ASPIRE Investigators. (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. The New England Journal of Medicine, 372, 142-152.
    • Stewart, A.K., Trudel, S., Bahlis, N.J., White, D., Sabry, W., Belch, A., Reiman, T., Roy, J., Shustik, C., Kovacs, M.J., Rubinger, M., Cantin, G., Song, K., Tompkins, K.A., Marcellus, D.C., Lacy, M.Q., Sussman, J., Reece, D., Brundage, M., Harnett, E.L., Shepherd, L., Chapman, J.A. & Meyer, R.M. (2013) A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: The National Cancer Institute of Canada clinicals trials group myeloma 10 trial. Blood, 121, 1517-1523.
    • Tacchetti, P., Pantani, L., De Stefano, V., Zamagni, E., Peccatori, J., Pezzi, A., Califano, C., Nozza, A., Tosi, P., Terragna, C., Ciambelli, F., Cangini, D., Galieni, P., Cangialosi, C., De Sabbata, G., Elice, F., Palumbo, A. & Cavo, M. (2014) Superior PFS2 with VTD vs TD for newly diagnosed, transplant eligible, multiple myeloma (MM) patients: Updated analysis of GIMEMA MMY3006 study. Blood (ASH Annual Meeting Abstracts), 124, 196.
    • (2013) Novel AKT inhibitor afuresertib in combination with bortezomib and dexamethasone demonstrates favorable safety profile and significant clinical activity in patients with Relapsed/Refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts), 122, 283.
    • Zahradova, L., Mollova, K., Ocadlikova, D., Kovarova, L., Adam, Z., Krejci, M., Pour, L., Krivanova, A., Sandecka, V. & Hajek, R. (2012) Efficacy and safety of id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results. Neoplasma, 59, 440-449.
    • Zamagni, E., Nanni, C., Mancuso, K., Tacchetti, P., Pezzi, A., Pantani, L., Zannetti, B., Rambaldi, I., Brioli, A., Rocchi, S., Terragna, C., Martello, M., Marzocchi, G., Borsi, E., Rizzello, I., Fanti, S. & Cavo, M. (2015) PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma. Clinical Cancer Research, 21, 4384-4390.
    • Zimmerman, T.M., Griffith, K.A., Jasielec, J., Rosenbaum, C.A., McDonnell, K., Waite-Marin, J., Berdeja, J.G., Raje, N.S., Reece, D.E., Vij, R., Alonge, M., Rosebeck, S., Gurbuxani, S., Faham, M., Kong, K.A., Levy, J. & Jakubowiak, A.J. (2015) Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). Journal of Clinical Oncology (ASCO Meeting Abstracts), 33, supplement 8510.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article